210 related articles for article (PubMed ID: 24935955)
1. Decreased HIV type 1 transcription in CCR5-Δ32 heterozygotes during suppressive antiretroviral therapy.
Wang C; Abdel-Mohsen M; Strain MC; Lada SM; Yukl S; Cockerham LR; Pilcher CD; Hecht FM; Sinclair E; Liegler T; Richman DD; Deeks SG; Pillai SK
J Infect Dis; 2014 Dec; 210(11):1838-43. PubMed ID: 24935955
[TBL] [Abstract][Full Text] [Related]
2. CCR5-Δ32 Heterozygosity, HIV-1 Reservoir Size, and Lymphocyte Activation in Individuals Receiving Long-term Suppressive Antiretroviral Therapy.
Henrich TJ; Hanhauser E; Harrison LJ; Palmer CD; Romero-Tejeda M; Jost S; Bosch RJ; Kuritzkes DR
J Infect Dis; 2016 Mar; 213(5):766-70. PubMed ID: 26512140
[TBL] [Abstract][Full Text] [Related]
3. HIV-1-infected long-term slow progressors heterozygous for delta32-CCR5 show significantly lower plasma viral load than wild-type slow progressors.
Walli R; Reinhart B; Luckow B; Lederer E; Loch O; Malo A; Wank R; Schlöndorff D; Goebel FD
J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Jul; 18(3):229-33. PubMed ID: 9665499
[TBL] [Abstract][Full Text] [Related]
4. Improved virological response to highly active antiretroviral therapy in HIV-1-infected patients carrying the CCR5 Delta32 deletion.
Laurichesse JJ; Persoz A; Theodorou I; Rouzioux C; Delfraissy JF; Meyer L
HIV Med; 2007 May; 8(4):213-9. PubMed ID: 17461848
[TBL] [Abstract][Full Text] [Related]
5. Viremic control and viral coreceptor usage in two HIV-1-infected persons homozygous for CCR5 Δ32.
Henrich TJ; Hanhauser E; Hu Z; Stellbrink HJ; Noah C; Martin JN; Deeks SG; Kuritzkes DR; Pereyra F
AIDS; 2015 May; 29(8):867-76. PubMed ID: 25730507
[TBL] [Abstract][Full Text] [Related]
6. Relationship between CCR5
Martínez-Bonet M; González-Serna A; Clemente MI; Morón-López S; Díaz L; Navarro M; Puertas MC; Leal M; Ruiz-Mateos E; Martinez-Picado J; Muñoz-Fernández MA
Clin Microbiol Infect; 2017 May; 23(5):318-324. PubMed ID: 28042001
[TBL] [Abstract][Full Text] [Related]
7. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation.
Hütter G; Nowak D; Mossner M; Ganepola S; Müssig A; Allers K; Schneider T; Hofmann J; Kücherer C; Blau O; Blau IW; Hofmann WK; Thiel E
N Engl J Med; 2009 Feb; 360(7):692-8. PubMed ID: 19213682
[TBL] [Abstract][Full Text] [Related]
8. MT-2 tropism and CCR-5 genotype strongly influence disease progression in HIV-1-infected individuals.
Bratt G; Leandersson AC; Albert J; Sandström E; Wahren B
AIDS; 1998 May; 12(7):729-36. PubMed ID: 9619804
[TBL] [Abstract][Full Text] [Related]
9. Is long-term virological response related to CCR5 Delta32 deletion in HIV-1-infected patients started on highly active antiretroviral therapy?
Laurichesse JJ; Taieb A; Capoulade-Metay C; Katlama C; Villes V; Drobacheff-Thiebaud MC; Raffi F; Chêne G; Theodorou I; Leport C;
HIV Med; 2010 Apr; 11(4):239-44. PubMed ID: 20050936
[TBL] [Abstract][Full Text] [Related]
10. Maraviroc Is Associated with Latent HIV-1 Reactivation through NF-κB Activation in Resting CD4
Madrid-Elena N; García-Bermejo ML; Serrano-Villar S; Díaz-de Santiago A; Sastre B; Gutiérrez C; Dronda F; Coronel Díaz M; Domínguez E; López-Huertas MR; Hernández-Novoa B; Moreno S
J Virol; 2018 May; 92(9):. PubMed ID: 29444937
[TBL] [Abstract][Full Text] [Related]
11. CCR5-edited CD4+ T cells augment HIV-specific immunity to enable post-rebound control of HIV replication.
Tebas P; Jadlowsky JK; Shaw PA; Tian L; Esparza E; Brennan AL; Kim S; Naing SY; Richardson MW; Vogel AN; Maldini CR; Kong H; Liu X; Lacey SF; Bauer AM; Mampe F; Richman LP; Lee G; Ando D; Levine BL; Porter DL; Zhao Y; Siegel DL; Bar KJ; June CH; Riley JL
J Clin Invest; 2021 Apr; 131(7):. PubMed ID: 33571163
[TBL] [Abstract][Full Text] [Related]
12. Combined effect of CCR5-Delta32 heterozygosity and the CCR5 promoter polymorphism -2459 A/G on CCR5 expression and resistance to human immunodeficiency virus type 1 transmission.
Hladik F; Liu H; Speelmon E; Livingston-Rosanoff D; Wilson S; Sakchalathorn P; Hwangbo Y; Greene B; Zhu T; McElrath MJ
J Virol; 2005 Sep; 79(18):11677-84. PubMed ID: 16140745
[TBL] [Abstract][Full Text] [Related]
13. Reduced HIV-1 infectability of CD4+ lymphocytes from exposed-uninfected individuals: association with low expression of CCR5 and high production of beta-chemokines.
Paxton WA; Liu R; Kang S; Wu L; Gingeras TR; Landau NR; Mackay CR; Koup RA
Virology; 1998 Apr; 244(1):66-73. PubMed ID: 9581779
[TBL] [Abstract][Full Text] [Related]
14. Heterozygosity for a defective gene for CC chemokine receptor 5 is not the sole determinant for the immunologic and virologic phenotype of HIV-infected long-term nonprogressors.
Cohen OJ; Vaccarezza M; Lam GK; Baird BF; Wildt K; Murphy PM; Zimmerman PA; Nutman TB; Fox CH; Hoover S; Adelsberger J; Baseler M; Arthos J; Davey RT; Dewar RL; Metcalf J; Schwartzentruber DJ; Orenstein JM; Buchbinder S; Saah AJ; Detels R; Phair J; Rinaldo C; Margolick JB; Pantaleo G; Fauci AS
J Clin Invest; 1997 Sep; 100(6):1581-9. PubMed ID: 9294127
[TBL] [Abstract][Full Text] [Related]
15. HIV-infected individuals with the CCR delta32/CCR5 genotype have lower HIV RNA levels and higher CD4 cell counts in the early years of the infection than do patients with the wild type. Copenhagen AIDS Cohort Study Group.
Katzenstein TL; Eugen-Olsen J; Hofmann B; Benfield T; Pedersen C; Iversen AK; Sørensen AM; Garred P; Koppelhus U; Svejgaard A; Gerstoft J
J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Sep; 16(1):10-4. PubMed ID: 9377119
[TBL] [Abstract][Full Text] [Related]
16. CC chemokine receptor 5 delta32 and CC chemokine receptor 2 64I polymorphisms do not influence the virologic and immunologic response to antiretroviral combination therapy in human immunodeficiency virus type 1-infected patients.
Wit FW; van Rij RP; Weverling GJ; Lange JM; Schuitemaker H
J Infect Dis; 2002 Dec; 186(12):1726-32. PubMed ID: 12447757
[TBL] [Abstract][Full Text] [Related]
17. HIV-1 infection in individuals with the CCR5-Delta32/Delta32 genotype: acquisition of syncytium-inducing virus at seroconversion.
Sheppard HW; Celum C; Michael NL; O'Brien S; Dean M; Carrington M; Dondero D; Buchbinder SP
J Acquir Immune Defic Syndr; 2002 Mar; 29(3):307-13. PubMed ID: 11873082
[TBL] [Abstract][Full Text] [Related]
18. Reduced prevalence of the CCR5 delta32 heterozygous genotype in human immunodeficiency virus-infected individuals with AIDS dementia complex.
van Rij RP; Portegies P; Hallaby T; Lange JM; Visser J; de Roda Husman AM; van 't Wout AB; Schuitemaker H
J Infect Dis; 1999 Sep; 180(3):854-7. PubMed ID: 10438379
[TBL] [Abstract][Full Text] [Related]
19. Associations of CCR5, CCR2, and stromal cell-derived factor 1 genotypes with human immunodeficiency virus disease progression in patients receiving nucleoside therapy.
Lathey JL; Tierney C; Chang SY; D'Aquila RT; Bettendorf DM; Alexander HC; Santini CD; Hughes AM; Barroga CF; Spector SA; Landes JE; Hammer SM; Katzenstein DA
J Infect Dis; 2001 Dec; 184(11):1402-11. PubMed ID: 11709782
[TBL] [Abstract][Full Text] [Related]
20. CC chemokine receptor 5 cell-surface expression in relation to CC chemokine receptor 5 genotype and the clinical course of HIV-1 infection.
de Roda Husman AM; Blaak H; Brouwer M; Schuitemaker H
J Immunol; 1999 Oct; 163(8):4597-603. PubMed ID: 10510404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
